阿凱迪亞生物科學 RKDA 深 滬
等待開盤 07-23 09:30:00 美东时间
0.65
-0.024
-3.63%
華盛通- 最 高0.68
- 今 開0.665
- 成交量 1.48万股
- 最 低 0.6212
- 昨 收 0.6745
- 總市值 386.12万
- 52周最高 6.71
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 0.59
- 委 比 94.46%
- 總股本 594.04万
- 歷史最高 7040.00
- 量 比 0.25
- 振 幅 8.72%
- 歷史最低 0.59
- 每 手 1
- 風險率 1.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arcadia Biosciences Grants CEO Bonus, Sets 2026 Meeting
Arcadia Biosciences ( ($RKDA) ) has shared an update. On July 1, 2026, Arcadia ...
07-03 04:50
Arcadia Biosciences Files Prospectus Pursuant To Which Selling Stockholders May Offer Up To 11.92M Shares Of Common Stock For Resale
https://www.sec.gov/Archives/edgar/data/1469443/000119312526285578/rkda-20260626.htm
06-27 04:39
Arcadia Biosciences dips 8% on $4M private placement
Arcadia Biosciences (RKDA) entered into securities purchase agreements for a private placement consisting of ~3.88M shares of common stock, along with Series A-1 and Series A-2 preferred investment op...
06-12 17:57
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences, Inc. (Nasdaq: RKDA) has entered into securities purchase agreements to sell 3,883,496 shares of its common stock and Series A-1 and A-2 preferred investment options, priced at $1.03 per share. The offering is expected to generate approximately $4 million in gross proceeds, with net proceeds to be used for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent. The Seri...
06-12 00:00
Arcadia Biosciences Q1 EPS $(2.11) Misses $(0.80) Estimate, Sales $1.100M Miss $1.600M Estimate
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.11) per share which missed the analyst consensus estimate of $(0.80) by 163.75 percent. This is a 211.05 percent decrease over earnings of $1.90 per
05-15 04:53
Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights
Arcadia Biosciences reported Q1 2026 results with Zola coconut water volumes up 18% YoY and SG&A at its lowest level as a public company. Despite a 8% revenue decline to $1.1M, the company remains focused on growing its Zola brand and launching new products. Operating expenses increased $1.2M, driven by higher costs and absence of prior year gains. Net loss widened to $4.4M, reflecting warrant inducement costs and other losses. Arcadia continues ...
05-14 20:05
12 Consumer Staples Stocks Moving In Friday's Pre-Market Session
Gainers 22nd Century Gr (NASDAQ:XXII) shares moved upwards by 19.2% to $1.86 d...
05-01 20:05
Arcadia Biosciences Q4 EPS $(0.97) Misses $(0.66) Estimate, Sales $901.000K Miss $1.400M Estimate
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.66) by 46.97 percent. This is a 67.45 percent increase over losses of $(2.98) per share
03-27 04:15
